Steel Stocks Move on Tariff News; Pharma Stocks Pop on Deal; Tesla Lower
Jun 2, 2025
Tariff news shakes up the steel market as US Steel faces a drop while Cleveland Cliffs rises amid the announcement of increased tariffs. Meanwhile, Bristol Myers makes headlines with a massive $11.1 billion deal for a cancer drug from BioNTech, signaling an exciting merger in pharmaceuticals. Tesla, however, is on the decline as new vehicle registrations dip in France, adding to struggles in the tech sector. It's a rollercoaster day for stocks!
03:59
forum Ask episode
web_stories AI Snips
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
insights INSIGHT
Steel Tariff Impact Mixed
Doubling U.S. steel and aluminum tariffs to 50% aims to protect American workers and industry.
The market shows mixed reactions: US Steel shares fall slightly while competitors like Cleveland Cliffs surge dramatically.
insights INSIGHT
Major Pharma Cancer Deal
Bristol Myers plans to pay BioNTech up to $11.1 billion for a next-gen cancer drug license.
This deal highlights a major payoff for BioNTech following their acquisition of a biotech company that developed the compound.
insights INSIGHT
Tesla Stock Falls on Sales Doubts
Tech stocks, including Tesla and Alphabet, are declining amid poor new-vehicle registrations in France.
Tesla’s founder Elon Musk’s recent sales recovery claim is questioned by this new data.
Get the Snipd Podcast app to discover more snips from this episode
- US Steel (X) shares are weaker this morning on news that President Trump is threatening to raise steel and aluminum tariffs. President Trump announced that he would increase tariffs on steel and aluminum to 50% from 25%, saying the move would help protect American workers. The deal would ensure the iconic American firm remains US-owned and operated, with Trump promising that US Steel workers would receive a $5,000 bonus and that $2.2 billion of the proposed investment would be earmarked to increase steel production.
- Cleveland Cliffs (CLF) is moving in the opposite direction of its competitor this morning as its rising on the tariff news. The president made the announcement during a visit to a United States Steel Corp. plant near Pittsburgh, where he championed an expected deal between US Steel and Japan's Nippon Steel Corp.
- Bristol Myers (BMY) is higher this morning along with the broader pharma sector as it agrees to pay BioNTech SE up to $11.1 billion to license a next-generation cancer drug, with $1.5 billion upfront and $2 billion in installments through 2028. The deal marks a major payoff for BioNTech, which initially licensed the compound from Chinese biotech Biotheus in 2023 and later bought the company outright for up to $950 million.
- Tesla (TSLA) is moving to the downside this morning along with other big names in the tech sector. It comes as new-vehicle registrations fell further in France, undercutting Chief Executive Officer Elon Musk’s assertion last month that the carmaker has recovered from its early-year sales slump.